CAMP4 THERAPEUTICS CORPORATION (CAMP)
Nasdaq · Healthcare · Biotechnology
$4.01+0.25%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $252M
- 52-week range
- $2.86 – $7.75
- 52-week change
- +21.58%
- EPS (trailing)
- −$2.32
- Analyst rating
- 1.3 Strong buy
Fiscal year to Dec 2025
- Revenue
- $3.5M (+436.50%)
- Net income
- −$80.4M
- Operating margin
- −1502.4%
- Diluted EPS
- −$2.65
- Free cash flow
- −$29.8M
From the company’s annual report on SEC EDGAR.
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 48 employees · camp4tx.com